Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to 2342.13%.

  • Addex Therapeutics' EBITDA Margin fell 11864200.0% to 2342.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 4891.58%, marking a year-over-year decrease of 36476900.0%. This contributed to the annual value of 634.13% for FY2024, which is 4958000.0% down from last year.
  • As of Q3 2025, Addex Therapeutics' EBITDA Margin stood at 2342.13%, which was down 11864200.0% from 12575.46% recorded in Q2 2025.
  • Addex Therapeutics' EBITDA Margin's 5-year high stood at 12575.46% during Q2 2025, with a 5-year trough of 182692.31% in Q4 2024.
  • For the 4-year period, Addex Therapeutics' EBITDA Margin averaged around 12719.03%, with its median value being 1343.09% (2024).
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -1812306000bps in 2024, then surged by 133574800bps in 2025.
  • Over the past 4 years, Addex Therapeutics' EBITDA Margin (Quarter) stood at 3463.7% in 2022, then skyrocketed by 58bps to 1461.7% in 2023, then plummeted by -12399bps to 182692.31% in 2024, then soared by 99bps to 2342.13% in 2025.
  • Its last three reported values are 2342.13% in Q3 2025, 12575.46% for Q2 2025, and 1559.6% during Q1 2025.